Goldenrod- New Uses in Pain Control for a Common Weed

Mar 1
07:03

2007

Peter Sinclair

Peter Sinclair

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

Surprising new use for the "Hay fever" weed, Goldenrod, in a new, clinicallyproven Arthritis Pain remedy

mediaimage
For most of us,Goldenrod- New Uses in Pain Control for a Common Weed Articles if we think about Goldenrod at all, it's because we are sensitive to pollen, and know every year when the golden blossoms appear in the field, we are beginning the season of allergies.

But healers around the world have known for centuries about the medicinal properties of Goldenrod as an herbal remedy. Now modern science is taking a closer look at this plant that most of us think of as a "weed".

The most common variety, Solidago virgaurea, or European Goldenrod is a perennial plant native to northern Europe that has become established on every continent. Other varieties are native to North America and north Africa, but have less pharmacological activity than Solidago virgaurea.

Goldenrod is an aquaretic, increasing renal blood flow and increasing glomerular filtration rate without stimulating the loss of electrolytes such as sodium and chloride. Aquaretics are considered safer than many synthetic diuretics that promote the loss of electrolytes. Goldenrod has been studied for its effects on diuresis and electrolyte balance, and its strong anti-inflammatory activity.

Goldenrod has been used to prevent the development of kidney stones, and to treat urinary tract inflammation. Goldenrod's aquaretic effects combined with both antimocrobila and anti-inflammatory properties allow this herb to be used in connection with a variety conditions which include Bladder inflammation, Arthritis, (ironically)Allergies, colds and flu, kidney stones, Laryngitis and sore throats.

As a component of the clinically proven arthritis pain remedy, Arthri-Zen, Goldenrod combines with juniper dandelion, meadowsweet, and willow, to provide remarkably effective pain relief, even for severe pain sufferers.

While just ten years ago it was estimated that arthritis affected 42 million Americans – or one in five adults – new data released by the Centers for Disease Control (CDC) show the disease is much more common than previously thought. The CDC now puts the number of adults in the U.S. with arthritis and chronic joint problems at 70 million – or one in three adults.

Arthri-Zen Relief¨ has been the subject of two clinical trials in the past, both showing it is effective at relieving the crippling pain of arthritis. A New 30-day trial, which was conducted by the independent Fenestra Research Labs, was undertaken to add to the scientific research supporting the product.

Seventy five subjects with extreme arthritis pain were recruited for the study. To qualify, subjects had to have daily pain at level 9 to 10 on a scale of 1-10. Fifty of the participants took Arthri-Zen Relief¨; 25took placebo.

The results were dramatic. Subjects taking placebo had no change in pain level during the study. By day 4, however, only 53.1 percent of those taking the Arthri-Zen Relief¨ were still at pain level 9-10. Threedays later, that figure dropped to 6.1 percent, and by day 7, it was 0 percent. On the tenth day, a full 85.7 percent of patients were reporting no pain at all. And by day 14, every single one of the people in the testgroup was completely pain-free. No rescue medications were allowed over the course of the 30-day trial – which means the effects were solely due to the Arthri-Zen Relief¨.

RZN Nutraceuticals founder, CEO and chief scientist Mark Lubin is thrilled with the results of the study, but he can’t say he’s entirely surprised. He developed the product for his own personal use after 13surgeries and countless prescription and OTC drugs failed him in his battle against a debilitating case of osteoarthritis. Today, he is completely mobile and pain-free, thanks to Arthri-Zen Relief¨. With three clinical trials supporting the product’s efficacy, he certainly won’t be the only one. RZN Nutraceuticals is located in Miami, Florida. RZN Nutraceutical founder, CEO and chief scientist Mark Lubin is a biomedical engineer who has 12 U.

S. patents issued or pending for biomedical andtechnical innovations. Arthri-Zen Relief¨ grew out of Lubin’s work to alleviate his own terrible arthritis pain and free himself from the ravaging toll pharmaceuticals were taking on his body. He later developed Migra-Zen Relief Plus¨ by making precise alterations to the Arthri-Zen Relief¨ formula. Both productsfeature a proprietary blend of herbs in a patent-pending delivery system. They are available in natural food stores nationwide and through the company’s website: http://www.rznnutra.com.

For more information on Migra-Zen Relief Plus¨ or any of the three Arthri-Zen Relief¨ formulations,please visit http://www.rznnutra.com or call Robert Hunt at 904-276-8324.?